Study to Assess the Effect of AZD4831 on the Pharmacokinetics (Drug Behavior in the Body) of Midazolam

The study will consist of 2 treatment periods and will comprise:

• A Screening period of maximum 28 days;
• Treatment Period 1 and Treatment Period 2:

Treatment Period 1: Midazolam only (Day 1). Treatment Period 2: AZD4831 only (Days 2 to 10, once daily dosing) and AZD4831 plus midazolam (Day 11).

• A final Follow-up Visit after the last administration of investigational medicinal product (IMP) (Day 20 [± 1 day]).

Each subject will be involved in the study for approximately 7 weeks.

Inclusion criteria

• Healthy male and/or female subjects with suitable veins for cannulation or repeated venepuncture.
• Males must be willing to use appropriate contraception methods.
• Females must not be lactating and must be of non-childbearing potential, confirmed at Screening.
• Have a body mass index between 18.5 and 30 kg/m^2 (inclusive) and weigh at least 50 kg and no more than 100 kg (inclusive) at Screening.

Exclusion criteria

• History of any clinically significant disease or disorder.
• History or presence of gastrointestinal, hepatic or renal disease, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
• A positive Corona Virus Disease 2019 test at Screening or admission to the Clinical Unit on Day -1.
• Any clinically significant abnormalities in clinical chemistry, haematology, or urinalysis results.
• Any clinically significant abnormal findings in vital signs.
• clinically significant abnormalities on 12-lead electrocardiogram.
• Any positive result at the Screening Visit for Hepatitis B surface antigen, hepatitis C virus antibody, and human immunodeficiency virus antibody.
• Known or suspected history of drug abuse in the last 2 years.
• Current smokers or those who have smoked or used nicotine products within the 3 months prior to the Screening Visit.
• Known or suspected history of alcohol or drug abuse.
• Use of any prescribed or non-prescribed medication.
• Subjects with acute pulmonary insufficiency, marked neuromuscular respiratory weakness, obsessional states, phobic states, sleep apnoea syndrome, or unstable myasthenia gravis.
• History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity, as judged by the investigatoror history of hypersensitivity to drugs with a similar chemical structure or class to AZD4831 or midazolam.
• History or ongoing allergy/hypersensitivity to drugs(including but not limited to rash, angioedema, acute urticaria).
• Subjects who, in the opinion of the Investigator, have any clinically significant skin condition.